Morell et al. showed that the use of enasidenib in combination with daunorubicin increased the effectiveness of daunorubicin by (i) inhibiting aldo-keto reductase 1C3 (AKR1C3), the expression of which in cancer cells promotes the development of insensitivity to anthracyclines; (ii) limiting the activity of ATP-binding cassette subfamily B member 1 (ABCB1), ATP-binding cassette subfamily G member 2 (ABCG2) and ATP-binding cassette subfamily C member 1 (ABCC1) transporters, which can pump chemotherapeutic agents out of the cancer cell. Here, AKR1C3 is linked to cancer.